Glitazones and heart failure: critical appraisal for the clinician.
Wang
Chao-Hung
CH
Division of Cardiac Surgery, Toronto General Hospital, University of Toronto, Toronto, Canada.
Weisel
Richard D
RD
Liu
Peter P
PP
Fedak
Paul W M
PW
Verma
Subodh
S
D000075202:Contraindications; D006321:Heart / Q000187:drug effects / Q000503:physiopathology; D006333:Heart Failure / Q000139:chemically induced / Q000517:prevention & control*; D006439:Hemodynamics / Q000187:drug effects; D006801:Humans; D017379:Hypertrophy, Left Ventricular / Q000188:drug therapy; D007004:Hypoglycemic Agents / Q000494:pharmacology / Q000627:therapeutic use*; D024821:Metabolic Syndrome / Q000188:drug therapy*; D008875:Middle Aged; D009200:Myocardial Contraction / Q000187:drug effects; D017202:Myocardial Ischemia / Q000188:drug therapy; D015428:Myocardial Reperfusion Injury / Q000188:drug therapy; D009206:Myocardium / Q000378:metabolism; D018377:Neurotransmitter Agents / Q000378:metabolism; D013844:Thiazoles / Q000494:pharmacology / Q000627:therapeutic use*; D014655:Vascular Resistance / Q000187:drug effects
D007004:Hypoglycemic Agents; D018377:Neurotransmitter Agents; D013844:Thiazoles